Krebs Biochem

Who are the top shareholders of the Krebs Biochem?

The top shareholders of Krebs Biochem are Ipca Laboratories Limited, holding 49.65%, and Sun Pharmaceutical Industries Ltd, the largest public shareholder with 4.81%. Individual investors own 20.42%, while foreign institutional investors hold 0.5%, and there are no mutual funds invested in the company.

The top shareholders of Krebs Biochem include its majority shareholders, who are the promoters. The promoter with the highest holding is Ipca Laboratories Limited, which owns 49.65% of the company. Additionally, Sun Pharmaceutical Industries Ltd is the highest public shareholder, holding 4.81%. Individual investors collectively hold 20.42% of the shares, while foreign institutional investors (FIIs) hold 0.5% through five different FIIs. There are no mutual funds currently invested in Krebs Biochem.

When is the next results date for Krebs Biochem?

No Upcoming Board Meetings

What does Krebs Biochem do?

Krebs Biochemicals & Industries Ltd manufactures Active Pharmaceutical Ingredients (API) through fermentation processes and is classified as a micro-cap company. As of March 2025, it reported net sales of 6 Cr and a net profit of -8 Cr.

Overview:<BR>Krebs Biochemicals & Industries Ltd is engaged in the manufacture of Active Pharmaceutical Ingredients (API) through fermentation processes, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in 1991 and was formerly known as Krebs Biochemicals Ltd. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 6 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -8 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 207 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -1.45 <BR>Return on Equity: 18.42% <BR>Price to Book: -1.18 <BR><BR>Contact Details:<BR>Address: Kothapalli(V) Kasimkota(M), Anakapalli Vishakapatnam Andhra Pradesh : 531031 <BR>Tel: 91-040-6680 8040 <BR>Email: investors@kerbsbiochem.com <BR>Website: http://www.krebsbiochem.com

Who are in the management team of Krebs Biochem?

As of March 2023, the management team of Krebs Biochem includes G V L Prasad (Independent Director), R T Ravi (Chairman), Avinash Ravi (Non-Executive Director), Tangirala Malati (Independent Director), Satish Khivsara (Independent Director), Raj Kamal Prasad Verma (Independent Director), Rohit Taparia (Company Secretary & Compliance Officer), and Jitendra Shah (Managing Director). The team features a mix of independent directors and executive roles.

As of March 2023, the management team of Krebs Biochem includes the following individuals:<BR><BR>1. G V L Prasad - Independent Director<BR>2. R T Ravi - Chairman (Non-Executive)<BR>3. Avinash Ravi - Non Executive Director<BR>4. Tangirala Malati - Independent Director<BR>5. Satish Khivsara - Independent Director<BR>6. Raj Kamal Prasad Verma - Independent Director<BR>7. Rohit Taparia - Company Secretary & Compliance Officer<BR>8. Jitendra Shah - Managing Director<BR><BR>This team comprises a mix of independent directors, executive roles, and compliance oversight.

Has Krebs Biochem declared dividend?

No Dividend History Available

Should I buy, sell or hold Krebs Biochem?

What is the technical trend for Krebs Biochem?

As of June 6, 2025, Krebs Biochem's technical trend has shifted to mildly bullish, supported by positive weekly MACD, KST, and Bollinger Bands, although daily moving averages suggest caution.

As of 6 June 2025, the technical trend for Krebs Biochem has changed from mildly bearish to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, supporting the positive shift in sentiment. The Bollinger Bands are also indicating a bullish stance on both weekly and monthly time frames. However, the daily moving averages remain mildly bearish, which suggests some caution. The Dow Theory shows a mixed signal with a mildly bullish weekly stance but a mildly bearish monthly outlook. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD, KST, and Bollinger Bands.

Who are the peers of the Krebs Biochem?

Krebs Biochem's peers include Bafna Pharma, Aarey Drugs, Panch.Organics, Astonea Labs, Auro Labs, Bal Pharma, BDH Industries, Tyche Industries, and Quest Laborato. Auro Labs leads in 1-year returns at 68.93%, while Krebs Biochem has a return of -1.68%.

Peers: The peers of Krebs Biochem are Bafna Pharma., Aarey Drugs, Panch.Organics, Astonea Labs, Auro Labs., Bal Pharma, BDH Industries, Tyche Industries, and Quest Laborato.<BR><BR>Quality Snapshot: Excellent management risk is observed at Auro Labs., BDH Industries, and Tyche Industries, while Average management risk is found at Aarey Drugs, Panch.Organics, Astonea Labs, and Bal Pharma. Below Average management risk is noted for Bafna Pharma. Growth is rated as Good for Bafna Pharma., Astonea Labs, Auro Labs., Bal Pharma, Quest Laborato., and Tyche Industries, while Below Average growth is seen at Aarey Drugs, Panch.Organics, and BDH Industries. Capital Structure is rated as Excellent for Panch.Organics and BDH Industries, Good for Bafna Pharma., Auro Labs., and Tyche Industries, and Below Average for Aarey Drugs, Astonea Labs, Bal Pharma, and Krebs Biochem.<BR><BR>Return Snapshot: Auro Labs. has the highest 1-year return at 68.93%, while Panch.Organics has the lowest at -45.84%. Krebs Biochem's 1-year return of -1.68% is better than Panch.Organics but worse than Auro Labs. Additionally, the six-month returns for Panch.Organics, Bal Pharma, BDH Industries, Tyche Industries, and Krebs Biochem are negative.

How big is Krebs Biochem?

As of 24th July, Krebs Biochemicals & Industries Ltd has a market capitalization of 172.00 Cr and reported Net Sales of 43.32 Cr, with a Net Profit loss of 26.94 Cr over the latest four quarters. Shareholder's Funds were at a loss of 119.22 Cr, while Total Assets were 178.17 Cr.

As of 24th July, Krebs Biochemicals & Industries Ltd has a market capitalization of 172.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 43.32 Cr. However, it experienced a loss of 26.94 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024. Shareholder's Funds were recorded at a loss of 119.22 Cr, while Total Assets amounted to 178.17 Cr.

How has been the historical performance of Krebs Biochem?

Krebs Biochem has experienced declining net sales and increasing losses, with total operating income falling from 59.70 Cr in Mar'22 to 43.31 Cr in Mar'25, and negative operating profit worsening from -33.99 Cr to -14.32 Cr during the same period. The company's financial health is further indicated by rising total liabilities and deteriorating shareholder equity, resulting in ongoing financial challenges.

Answer:<BR>The historical performance of Krebs Biochem shows a trend of declining net sales and increasing losses over the years.<BR><BR>Breakdown:<BR>Krebs Biochem's net sales decreased from 52.94 Cr in Mar'22 to 43.31 Cr in Mar'25, reflecting a downward trend. Other operating income, which was 6.76 Cr in Mar'22, has dropped to zero by Mar'25, contributing to a total operating income decline from 59.70 Cr in Mar'22 to 43.31 Cr in Mar'25. The total expenditure, excluding depreciation, has also decreased from 93.69 Cr in Mar'22 to 58.34 Cr in Mar'25. However, the operating profit (PBDIT) remains negative, worsening from -33.99 Cr in Mar'22 to -14.32 Cr in Mar'25. The profit before tax and profit after tax have shown similar negative trends, with losses increasing from -44.53 Cr and -44.53 Cr in Mar'22 to -26.92 Cr and -26.94 Cr in Mar'25, respectively. The company's total liabilities have increased from 159.22 Cr in Mar'21 to 169.04 Cr in Mar'25, while shareholder's funds have deteriorated, showing a negative value of -146.24 Cr in Mar'25. The cash flow from operating activities has remained negative, indicating ongoing financial challenges. Overall, Krebs Biochem's financial performance has been characterized by declining revenues, increasing losses, and deteriorating equity over the years.

Are Krebs Biochemicals & Industries Ltd latest results good or bad?

Krebs Biochemicals & Industries Ltd's latest results are concerning, showing a net loss of ₹3.13 crores and a negative net worth of ₹146.24 crores, despite some operational improvements. The company is categorized as a "Strong Sell" due to its ongoing financial distress.

Krebs Biochemicals & Industries Ltd's latest results indicate a challenging financial situation. In Q3 FY26, the company reported a net loss of ₹3.13 crores, which is a significant decline of 59.45% compared to the previous quarter and 59.56% year-on-year. While revenue showed a sequential improvement of 74.34%, reaching ₹7.27 crores, this figure still represents a 36.62% decrease from the same quarter last year.<BR><BR>The operating margin turned positive at 3.99%, a notable recovery from the previous quarter's -66.91%. However, the profit after tax (PAT) margin remains negative at -43.05%, despite an improvement from -147.24% in Q2 FY26. This suggests that while there are some signs of operational improvement, the overall financial health of the company is still precarious.<BR><BR>The balance sheet reflects serious concerns, with a negative net worth of ₹146.24 crores and long-term debt of ₹161.25 crores. The company's market capitalization is only ₹125 crores, and it has been categorized as a "Strong Sell" due to its financial distress.<BR><BR>In summary, while there are some marginal improvements in operational metrics, the overall results are concerning, indicating a company still facing significant challenges and risks.

Why is Krebs Biochemicals & Industries Ltd falling/rising?

As of 03-Apr, Krebs Biochemicals & Industries Ltd is seeing a short-term stock price increase to 45.60, attributed to recent gains and sector outperformance. However, the company faces significant long-term challenges, including a -37.45% return over the past year and declining investor participation.

As of 03-Apr, Krebs Biochemicals & Industries Ltd is experiencing a rise in its stock price, currently at 45.60, with a change of 0.64 (1.42%) upward. This increase can be attributed to the stock outperforming its sector by 2.25% today and achieving consecutive gains over the last two days, resulting in a notable return of 13.97% during this period. <BR><BR>Despite these short-term gains, the stock has faced significant challenges in the longer term, as evidenced by its performance metrics. Over the past year, the stock has generated a return of -37.45%, and it has consistently reported negative results for the last five consecutive quarters, with net sales declining by 52.98% in the latest six months. Additionally, the company has a negative EBITDA of Rs. -10 cr, indicating ongoing financial struggles.<BR><BR>Investor participation has also been declining, as shown by a significant drop in delivery volume, which fell by 69.14% against the five-day average. Furthermore, the stock's moving averages indicate that while it is currently higher than the five-day moving average, it remains lower than the 20-day, 50-day, 100-day, and 200-day moving averages, suggesting potential volatility.<BR><BR>In summary, while Krebs Biochemicals & Industries Ltd is currently rising in price due to recent short-term gains and sector outperformance, it faces substantial long-term challenges that could affect its stability and future performance.

Why is Krebs Biochemicals & Industries Ltd falling/rising?

As of 04-Apr, Krebs Biochemicals & Industries Ltd's stock price has risen to 45.60, reflecting a 1.42% increase, driven by short-term gains. However, the stock has significant long-term declines, with a year-to-date drop of 34.52%, and decreasing investor participation suggests potential underlying challenges.

As of 04-Apr, Krebs Biochemicals & Industries Ltd is experiencing a rise in its stock price, currently at 45.60, with a change of 0.64 (1.42%) upward. This increase can be attributed to the stock outperforming its sector by 2.25% today and achieving consecutive gains over the last two days, resulting in a total return of 13.97% during this period. <BR><BR>Despite the positive short-term performance, it is important to note that the stock has faced significant declines over longer periods, with a year-to-date drop of 34.52% and a one-year decline of 37.45%. Additionally, while the stock is currently trading above its 5-day moving average, it remains below its 20-day, 50-day, 100-day, and 200-day moving averages, indicating that it may still be under pressure in the longer term.<BR><BR>Investor participation has also decreased, as evidenced by a delivery volume of 6.3k on April 1, which represents a decline of 69.14% compared to the 5-day average. This reduction in participation could suggest a lack of confidence among investors, despite the recent price increase. Overall, while the stock is currently rising, its longer-term performance and declining investor participation may indicate underlying challenges.

Why is Krebs Biochemicals & Industries Ltd falling/rising?

As of 05-Apr, Krebs Biochemicals & Industries Ltd's stock price has risen to 45.60, reflecting a 1.42% increase, driven by recent gains. However, the stock has significant long-term declines and decreasing investor participation, indicating ongoing challenges.

As of 05-Apr, Krebs Biochemicals & Industries Ltd is experiencing a rise in its stock price, currently at 45.60, with a change of 0.64 (1.42%) upwards. This increase can be attributed to the stock outperforming its sector by 2.25% today and achieving consecutive gains over the last two days, resulting in a total return of 13.97% during this period. <BR><BR>Despite the positive movement today, it is important to note that the stock has faced significant declines over longer periods, with a year-to-date drop of 34.52% and a one-year decline of 37.45%. Additionally, while the stock is currently trading above its 5-day moving average, it remains below its 20-day, 50-day, 100-day, and 200-day moving averages, indicating that it may still be under pressure in the longer term.<BR><BR>Investor participation has also decreased, as evidenced by a delivery volume of 6.3k on April 1, which represents a decline of 69.14% compared to the 5-day average. This reduction in participation could suggest a lack of confidence among investors, despite the recent price increase. Overall, while the stock is rising today, its longer-term performance and declining investor participation indicate ongoing challenges.

Which are the latest news on Krebs Biochem?

Which are the latest news on Krebs Biochem?

Which are the latest news on Krebs Biochem?